The PE Ratio as of September 2024 (TTM) for Entrada Therapeutics, Inc. (TRDA) is 4.88

According to Entrada Therapeutics, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is 4.88. This represents a change of -928.93% compared to the average of -0.59 of the last 4 quarters.

Entrada Therapeutics, Inc. (TRDA) Historical PE Ratio (quarterly & annually)

How has TRDA PE Ratio performed in the past?

The mean historical PE Ratio of Entrada Therapeutics, Inc. over the last ten years is -55.89. The current 4.88 PE Ratio has changed -973.08% with respect to the historical average. Over the past ten years (40 quarters), TRDA's PE Ratio was at its highest in in the March 2024 quarter at 4.90. The PE Ratio was at its lowest in in the March 2023 quarter at -17.58.

Entrada Therapeutics, Inc. (TRDA) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Entrada Therapeutics, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Entrada Therapeutics, Inc. (TRDA) Average PE Ratio

How has TRDA PE Ratio performed in the past?

The current PE Ratio of Entrada Therapeutics, Inc. (TRDA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Entrada Therapeutics, Inc. (TRDA) PE Ratio vs. Peers

How is TRDA’s PE Ratio compared to its peers?

Entrada Therapeutics, Inc.’s PE Ratio is greater than Molecular Partners AG (-2.54), greater than PMV Pharmaceuticals, Inc. (-1.60), greater than Monte Rosa Therapeutics, Inc. (-3.11), greater than Vigil Neuroscience, Inc. (-1.73), greater than Third Harmonic Bio, Inc. (-28.77), greater than Cullinan Oncology, Inc. (-6.53), greater than Edgewise Therapeutics, Inc. (-13.57), greater than Rallybio Corporation (-0.67), greater than Crinetics Pharmaceuticals, Inc. (-16.50), greater than Centessa Pharmaceuticals plc (-11.37), greater than Disc Medicine, Inc. (-13.62), greater than Larimar Therapeutics, Inc. (-7.39), greater than PepGen Inc. (-3.36), greater than Tyra Biosciences, Inc. (-14.58), greater than Pharvaris N.V. (-9.01), less than Eliem Therapeutics, Inc. (0), greater than Genenta Science S.p.A. (-3.91), greater than Opthea Limited (-5.13), greater than Pardes Biosciences, Inc. (-1.28), greater than null (-1.36),

Build a custom stock screener for Entrada Therapeutics, Inc. (TRDA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Entrada Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Entrada Therapeutics, Inc. (TRDA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Entrada Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.